Garamycin 40 mg/ml Injektionsvätska, lösning Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

garamycin 40 mg/ml injektionsvätska, lösning

schering plough europe - gentamicinsulfat - injektionsvätska, lösning - 40 mg/ml - gentamicinsulfat aktiv substans; propylparahydroxibensoat hjälpämne; natriummetabisulfit hjälpämne; metylparahydroxibensoat hjälpämne - gentamicin

Garamycin 80 mg/ml Injektionsvätska, lösning Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

garamycin 80 mg/ml injektionsvätska, lösning

schering plough europe - gentamicinsulfat - injektionsvätska, lösning - 80 mg/ml - gentamicinsulfat aktiv substans; propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne; natriummetabisulfit hjälpämne - gentamicin

Celeston valerat med gentamicin vet. Kräm Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

celeston valerat med gentamicin vet. kräm

schering-plough a/s - betametasonvalerat; gentamicinsulfat - kräm - betametasonvalerat 1,22 mg aktiv substans; gentamicinsulfat aktiv substans; klorkresol hjälpämne; cetostearylalkohol hjälpämne - betametason och antibiotika - samtliga

Septopal 4,5 mg Kedja för implantation Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

septopal 4,5 mg kedja för implantation

merck kgaa - gentamicinsulfat; zirkoniumdioxid - kedja för implantation - 4,5 mg - zirkoniumdioxid 20 mg aktiv substans; gentamicinsulfat 7,5 mg aktiv substans - gentamicin

Garamycin 0,1 % Kräm Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

garamycin 0,1 % kräm

schering plough europe - gentamicinsulfat - kräm - 0,1 % - cetostearylalkohol hjälpämne; klorkresol hjälpämne; gentamicinsulfat aktiv substans - gentamicin

Otomax vet. Örondroppar, suspension Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

otomax vet. örondroppar, suspension

intervet international b.v. - betametasonvalerat; gentamicinsulfat; klotrimazol - Örondroppar, suspension - gentamicinsulfat 2640 ie aktiv substans; betametasonvalerat 1,07 mg aktiv substans; klotrimazol 8,8 mg aktiv substans - betametason och antiinfektiva medel - hund

Purevax RC Europese Unie - Zweeds - EMA (European Medicines Agency)

purevax rc

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals för kattdjur, - katter - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Purevax RCP Europese Unie - Zweeds - EMA (European Medicines Agency)

purevax rcp

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals för kattdjur, - katter - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Purevax RCP FeLV Europese Unie - Zweeds - EMA (European Medicines Agency)

purevax rcp felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals för kattdjur, - katter - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Purevax RCPCh Europese Unie - Zweeds - EMA (European Medicines Agency)

purevax rcpch

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals för kattdjur, - katter - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immunitetens intrång har visats en vecka efter primärvaccinationskurs för rinotrakeit, kalicivirus, chlamydophila felis och panleukopeni-komponenter. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.